Kim H, Lee D, Song J, Kim H, Lee S, Shin S
Nutr Res Pract. 2025; 19(1):14-29.
PMID: 39959743
PMC: 11821778.
DOI: 10.4162/nrp.2025.19.1.14.
Yu L, Qin J, Zhang M, Gao Y, Zhao Y
Drug Des Devel Ther. 2024; 18:6089-6113.
PMID: 39717199
PMC: 11664478.
DOI: 10.2147/DDDT.S489377.
Xie C, Zhou X, Wu J, Chen W, Ren D, Zhong C
Cell Death Dis. 2024; 15(11):792.
PMID: 39500884
PMC: 11538260.
DOI: 10.1038/s41419-024-07197-1.
Wang Y, Wang S, Li M, Zhang Q, Fang M, Zheng Q
Am J Transl Res. 2024; 16(9):4320-4342.
PMID: 39398618
PMC: 11470291.
DOI: 10.62347/VKMZ3204.
Hu Q, Li L, Li Y, Zhang H, Deng T, Liu Y
Acta Pharmacol Sin. 2024; 46(3):740-750.
PMID: 39384887
PMC: 11845602.
DOI: 10.1038/s41401-024-01394-6.
Functional roles of conserved lncRNAs and circRNAs in eukaryotes.
Li J, Wang X
Noncoding RNA Res. 2024; 9(4):1271-1279.
PMID: 39036601
PMC: 11260338.
DOI: 10.1016/j.ncrna.2024.06.014.
Rational design of small-sized peptidomimetic inhibitors disrupting protein-protein interaction.
Wang J, Zheng P, Yu J, Yang X, Zhang J
RSC Med Chem. 2024; 15(7):2212-2225.
PMID: 39026653
PMC: 11253864.
DOI: 10.1039/d4md00202d.
Unveiling the Mechanisms of EGCG-p53 Interactions through Molecular Dynamics Simulations.
Bahena Culhuac E, Bello M
ACS Omega. 2024; 9(18):20066-20085.
PMID: 38737068
PMC: 11080030.
DOI: 10.1021/acsomega.3c10523.
Cymensifin A: a promising pharmaceutical candidate to defeat lung cancer via cellular reactive oxygen species-mediated apoptosis.
Soares B, Khine H, Sritularak B, Chanvorachote P, Alduina R, Sungthong R
Front Pharmacol. 2024; 15:1361085.
PMID: 38666017
PMC: 11043475.
DOI: 10.3389/fphar.2024.1361085.
A Predictive Noninvasive Single-Nucleotide Variation-Based Biomarker Signature for Resectable Pancreatic Cancer: Protocol for a Prospective Validation Study.
Seeger N, Gutknecht S, Zschokke I, Fleischmann I, Roth N, Metzger J
JMIR Res Protoc. 2024; 13:e54042.
PMID: 38635586
PMC: 11130767.
DOI: 10.2196/54042.
Regulation and therapeutic potentials of microRNAs to non-small cell lung cancer.
Le M, Nguyen H, Nguyen X, Do X, Mai B, Ngoc Nguyen H
Heliyon. 2023; 9(11):e22080.
PMID: 38058618
PMC: 10696070.
DOI: 10.1016/j.heliyon.2023.e22080.
Enhanced reactivation disrupts transcriptional program and overcomes venetoclax resistance in acute myeloid leukemias.
Nishida Y, Ishizawa J, Ayoub E, Heinz Montoya R, Ostermann L, Muftuoglu M
Sci Adv. 2023; 9(48):eadh1436.
PMID: 38019903
PMC: 10686564.
DOI: 10.1126/sciadv.adh1436.
Cell Death Pathway Regulation by Functional Nanomedicines for Robust Antitumor Immunity.
Li Y, Guo Y, Zhang K, Zhu R, Chen X, Zhang Z
Adv Sci (Weinh). 2023; 11(3):e2306580.
PMID: 37984863
PMC: 10797449.
DOI: 10.1002/advs.202306580.
Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy.
Li Y, Liu Y, Yang K, Jin L, Yang J, Huang S
Cancer Cell Int. 2023; 23(1):281.
PMID: 37981695
PMC: 10657579.
DOI: 10.1186/s12935-023-03122-2.
A transcriptome study of p53-pathway related prognostic gene signature set in bladder cancer.
Khan S, Das T, Chakraborty S, Choudhury A, Karim H, Mostofa M
Heliyon. 2023; 9(10):e21058.
PMID: 37876438
PMC: 10590981.
DOI: 10.1016/j.heliyon.2023.e21058.
Real-world routine diagnostic molecular analysis for TP53 mutational status is recommended over p53 immunohistochemistry in B-cell lymphomas.
de Haan L, de Groen R, de Groot F, Noordenbos T, van Wezel T, van Eijk R
Virchows Arch. 2023; 485(4):643-654.
PMID: 37851120
PMC: 11522076.
DOI: 10.1007/s00428-023-03676-6.
Proteomics Profiling of Bladder Cancer Tissues from Early to Advanced Stages Reveals NNMT and GALK1 as Biomarkers for Early Detection and Prognosis of BCa.
Davalieva K, Kiprijanovska S, Ivanovski O, Trifunovski A, Saidi S, Dimovski A
Int J Mol Sci. 2023; 24(19).
PMID: 37834386
PMC: 10573217.
DOI: 10.3390/ijms241914938.
Dynamic full-field optical coherence tomography module adapted to commercial microscopes allows longitudinal in vitro cell culture study.
Monfort T, Azzollini S, Brogard J, Clemencon M, Slembrouck-Brec A, Forster V
Commun Biol. 2023; 6(1):992.
PMID: 37770552
PMC: 10539404.
DOI: 10.1038/s42003-023-05378-w.
CSE1L is a negative regulator of the RB-DREAM pathway in p53 wild-type NSCLC and can be targeted using an HDAC1/2 inhibitor.
Duan L, Tadi M, Maki C
Sci Rep. 2023; 13(1):16271.
PMID: 37759078
PMC: 10533896.
DOI: 10.1038/s41598-023-43218-3.
miR-3133 inhibits gastrointestinal cancer progression through activation of Hippo and p53 signalling pathways via multi-targets.
Zhou L, Guo H, Liao Q, Zou J, Le Y, Fang Z
J Cell Mol Med. 2023; 27(20):3090-3106.
PMID: 37555915
PMC: 10568676.
DOI: 10.1111/jcmm.17880.